Review
Medicine, General & Internal
Chienhsiu Huang, Ihung Chen, Tiju Tang
Summary: This meta-analysis compared the efficacy and safety of colistin monotherapy and colistin plus meropenem combination therapy in patients with drug-resistant Acinetobacter baumannii infection. The results showed that colistin monotherapy had similar clinical outcomes and safety profile compared to the combination therapy, with the exception of microbiological response, where the combination therapy was superior.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Infectious Diseases
Xingchen Bian, Xiaofen Liu, Meiqing Feng, Phillip J. Bergen, Jian Li, Yuancheng Chen, Huajun Zheng, Sichao Song, Jing Zhang
Summary: This study conducted whole genome sequencing on carbapenem-resistant Acinetobacter baumannii isolates and investigated the bacterial killing effects of colistin and sulbactam combination therapy. The results showed that higher sulbactam concentration and longer infusion time substantially enhanced bacterial killing in a dynamic model.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Infectious Diseases
Rujipas Sirijatuphat, Supawas Thawornkaew, Darat Ruangkriengsin, Visanu Thamlikitkul
Summary: This study aimed to compare the efficacy and safety between colistin plus sitafloxacin and colistin alone for treating CR A. baumannii infection. The results showed no significant difference in 28-day mortality, clinical and microbiological responses, and adverse events between the two treatment groups.
Article
Immunology
Shruti Kashyap, Sukhvir Kaur, Prince Sharma, Neena Capalash
Summary: The combination of tobramycin and colistin has shown promising results in eradicating persister cells of Acinetobacter baumannii, suggesting a potential strategy for preventing relapse of infections caused by this pathogen.
MICROBES AND INFECTION
(2021)
Article
Microbiology
Hadas Kon, Amichay Hameir, Elizabeth Temkin, Alona Keren-Paz, David Schwartz, Vered Schechner, Yehuda Carmeli
Summary: This study aimed to investigate the emergence of colistin-dependent (CD) strains in carbapenem-resistant Acinetobacter baumannii (CRAB) isolates with colistin heteroresistance, and to examine the phenotypic characteristics and evolution of CD strains. The study also found that CD strains exhibited increased susceptibilities to multiple antibiotics, but the detection of CD strains in blood cultures was significantly delayed.
Article
Infectious Diseases
Jacinda C. Abdul-Mutakabbir, Juwon Yim, Logan Nguyen, Philip T. Maassen, Kyle Stamper, Zain Shiekh, Razieh Kebriaei, Ryan K. Shields, Mariana Castanheira, Keith S. Kaye, Michael J. Rybak
Summary: The study explored the potential utility of antibiotic combinations for carbapenem-resistant Acinetobacter baumannii isolates, identifying synergistic and bactericidal effects in certain combination therapies. Results suggest that certain antibiotic combinations can restore efficacy against resistant strains, offering new treatment options for difficult-to-treat infections caused by Acinetobacter baumannii.
Article
Infectious Diseases
Andrea Miro-Canturri, Rafael Ayerbe-Algaba, Manuel Enrique Jimenez-Mejias, Jeronimo Pachon, Younes Smani
Summary: The study found that LPC in combination with colistin treatment inhibited multidrug-resistant Acinetobacter baumannii infection in mice and reduced the mortality rate of the mice.
Article
Microbiology
Miaomiao Xie, Kaichao Chen, Edward Wai-Chi Chan, Sheng Chen
Summary: Findings in this study provide concrete evidence that antimicrobial activity of colistin can be significantly enhanced by using econazole, an antifungal drug, as a colistin adjuvant. The drug combination is effective in killing multidrug-resistant Acinetobacter baumannii strains as well as the tolerant subpopulation known as persisters. The synergistic effect of the drug combination was observed in mouse infection models at low concentrations, indicating its high potential for clinical use.
MICROBIOLOGY SPECTRUM
(2022)
Article
Immunology
Ryan K. Shields, David L. Paterson, Pranita D. Tamma
Summary: Acinetobacter baumannii-calcoaceticus complex is a common cause of nosocomial infections with high antibiotic resistance. Traditional combination therapy includes colistin, sulbactam, and tetracyclines. New beta-lactam agents like cefiderocol and sulbactam-durlobactam have shown contrasting results in recent clinical trials. Effective treatment for CRAB infections requires a personalized approach considering host factors, site of infection, pharmacokinetic-pharmacodynamic principles, and local molecular epidemiology.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Microbiology
Go Kamoshida, Noriteru Yamada, Tomoka Nakamura, Daiki Yamaguchi, Daichi Kai, Maho Yamashita, Chiaki Hayashi, Nana Kanda, Moe Sakaguchi, Hitoshi Morimoto, Teppei Sawada, Tomoko Okada, Yuki Kaya, Norihiko Takemoto, Kinnosuke Yahiro
Summary: This study reveals the mechanism of resistance to colistin in Acinetobacter baumannii, showing that strains with mutations in lpxACD genes can emerge under the selection pressure of colistin, resulting in LPS-deficient colistin-resistant strains. Compared to LPS-deficient strains, strains with modified LPS have a higher fitness and resistance.
MICROBIOLOGY SPECTRUM
(2022)
Article
Infectious Diseases
Maxime Bouvier, Mustafa Sadek, Stefano Pomponio, Fernando D'Emidio, Laurent Poirel, Patrice Nordmann
Summary: The RapidResa Polymyxin Acinetobacter NP(R) test showed 96% sensitivity and 97% specificity in rapidly detecting polymyxin resistance in Acinetobacter baumannii, with a turnaround time of 3-4 hours, indicating excellent reliability for clinical use.
Article
Biochemistry & Molecular Biology
Jovana Kabic, Katarina Novovic, Dusan Kekic, Anika Trudic, Natasa Opavski, Ivica Dimkic, Branko Jovcic, Ina Gajic
Summary: This study aimed to investigate the prevalence and resistance mechanisms of colistin-resistant Acinetobacter baumannii (ColRAB) isolates in Serbia, assess their genetic relatedness to other circulating A. baumannii isolates in the neighbouring European countries, and analyse the global genomic epidemiology of ColRAB isolates. The findings reveal the central role of the twocomponent regulating system, PmrAB, and increased expression of the pmrC gene in colistin resistance in A. baumannii. The study also highlights the global dissemination of several high-risk clonal lineages of ColRAB isolates.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2023)
Article
Microbiology
Yining Zhao, Yan Liu, Luozhu Feng, Mengxin Xu, Hong Wen, Zhuocheng Yao, Shiyi Shi, Qing Wu, Cui Zhou, Jianming Cao, Tieli Zhou
Summary: This study evaluated the antibacterial activity of chrysin in combination with colistin against Acinetobacter baumannii. The results showed that chrysin and colistin exerted synergistic effects against A. baumannii by damaging the extracellular membrane and modifying the bacterial membrane potential. The chrysin/colistin combination also demonstrated an inhibitory effect on biofilm formation. Therefore, the combination therapy of chrysin/colistin may provide a new therapeutic option for controlling A. baumannii infections.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Infectious Diseases
Feyza Izci, Zeynep Ture, Gokcen Dinc, Arzu Hanim Yay, Esma Eryilmaz Eren, Demet Bolat, Zeynep Burcin Goenen, Gamze Kalin Unuvar, Orhan Yildiz, Bilgehan Aygen
Summary: This study investigates the potential role of MSCs in reducing bacterial loads and preventing histopathological damage in a CRAB sepsis model when combined with colistin-fosfomycin treatment.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Nalumon Thadtapong, Soraya Chaturongakul, Sunhapas Soodvilai, Padungsri Dubbs
Summary: This study focused on analyzing the whole genome data of Aci46, and found that it belongs to the Pasture ST2 cluster and is phylogenetically clustered with the international clone (IC) II, a predominant strain in Thailand. Interestingly, Aci46 is identical to Oxford ST1962, which has never been isolated in Thailand before. The presence of potential virulence-associated factors and antibiotic resistance phenotypes were explored in the study.
Review
Infectious Diseases
Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman
Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)
Article
Infectious Diseases
Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri
Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2024)